Moreover, LRP6 overexpression had been associated to a more aggressive BC phenotype in a smaller cohort of patients, and its down-regulation was sufficient to inhibit tumorigenesis, suggesting it as a possible, new, promising therapeutic target [30]. This evidence concerns the gene LRP6 and breast cancer.